Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Alkermes ( (ALKS) ) has provided an update.
On October 22, 2025, Alkermes announced its agreement to acquire Avadel Pharmaceuticals for up to $2.1 billion, enhancing its presence in the sleep medicine market with Avadel’s product LUMRYZ. The acquisition is expected to be immediately accretive and will strengthen Alkermes’ commercial portfolio and revenue growth, positioning it as a leader in treatments for sleep and neurological disorders.
The most recent analyst rating on (ALKS) stock is a Buy with a $37.00 price target. To see the full list of analyst forecasts on Alkermes stock, see the ALKS Stock Forecast page.
Spark’s Take on ALKS Stock
According to Spark, TipRanks’ AI Analyst, ALKS is a Outperform.
Alkermes receives a strong overall score driven by its robust financial performance and positive earnings call sentiment. The technical analysis supports a bullish outlook, although valuation is moderate. The absence of significant corporate events does not impact the score.
To see Spark’s full report on ALKS stock, click here.
More about Alkermes
Alkermes is a biopharmaceutical company that focuses on developing innovative medicines in the fields of neuroscience and oncology. Its primary products and services include treatments for central nervous system disorders, with a market focus on sleep medicine and neurological disorders.
Average Trading Volume: 1,896,036
Technical Sentiment Signal: Strong Buy
Current Market Cap: $5.11B
See more insights into ALKS stock on TipRanks’ Stock Analysis page.